Inductive Bio is a New York company [1] that applies data and machine learning models to address small molecule ADMET problems [1]. ADMET refers to the absorption, distribution, metabolism, excretion, and toxicity properties that are critical considerations in drug development. The company's approach leverages computational methods to analyze and predict these molecular characteristics, supporting the drug discovery process.
Funding history
- Inductive Bio said it was supported by leading investors at the intersection of technology and biotechnology, including a16z and Lux.[5]
Traction
- Inductive Bio claimed three consecutive 1st place finishes in the world's largest ADMET benchmarks, including an OpenADMET and ExpansionRx blind challenge where Beacon-1 outperformed 370+ submissions across 9 endpoints and 2,250 compounds.[3]
Product
- Inductive Bio sold its Beacon-1 class of ADMET AI models trained on a pre-competitive data consortium, Compass software for running virtual experiments and reviewing predictions, and Indy, an AI chemistry assistant.[2]
Customers
- Biopharma companies named on Inductive Bio's site among its customers and testimonials included Belharra, Augustine Therapeutics, Light Horse Therapeutics, Arrakis, Dewpoint, Gandeeva, Nexo Therapeutics, Rapport and Tenvie.[6]
Partnerships
- Inductive Bio said it is leading a $21M ARPA-H initiative with Amgen and top academic institutions to develop AI drug toxicity models.[4]
Backers
AlleyCorp
New York venture firm founded by Kevin Ryan that founds and invests in transformative companies in New York and worldwide, incubating startups and backing early-stage companies such as MongoDB, Business Insider and Gilt Groupe.
AlleyCorp is a venture capital firm and startup incubator that founds and invests in early-stage technology companies across various sectors.
Something wrong or missing? Send a correction. Fixed within 24 hours.